Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

For patients with breast cancer, moderate hypofractionation (MHF) shows an improved safety profile, cosmesis, and quality of ...

The guidance is geared towards sponsors who conduct oncology therapy trials in more than one country under a single protocol.

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer, prostate ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Corcept Therapeutics (CORT – Research Report). The ...

In a report released yesterday, Sachin Jain from Bank of America Securities reiterated a Buy rating on Genmab A/S (0MGB – Research ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.17, ...

The following is a summary of “Comparing Frailty Indices for Risk Stratification in Urologic Oncology: Which Index to Choose?

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether ...

Indicators of a response to radiation therapy include pain relief and a return to baseline function or improved function. Patients may experience some relief of symptoms within a few days after ...